Gilead Sciences said its two key hepatitis C drugs, Sovaldi and Harvoni, had about $3.84 billion in sales in the December quarter, easing concerns about rising competition.
from WSJ.com: US Business http://ift.tt/1AquDTB
via IFTTT
from WSJ.com: US Business http://ift.tt/1AquDTB
via IFTTT
No comments:
Post a Comment